Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The Life Science AI business posted higher revenue due to the accumulation of co-creation project contracts and DDAIF Innovation Bridge contracts, as well as one-time revenue related to AI medical device development. However, the business recorded an operating loss due to growth investments, including the expansion of its research staff. The Risk Management business posted lower revenue due to the cancellation of a major customer contract, delays in winning new projects, a decline in e-discovery projects, cancellations of private-sector projects, and the concentration of government projects in the second half. The DX business posted higher revenue and profit due to increased sales.
There are no applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥3,292 million (YoY -2.5%) |
| Operating profit | ¥-244 million |
| Ordinary income | ¥-229 million |
| Profit attributable to owners of the parent | ¥-186 million |
| Net income per share | -¥4.77 |
| Equity ratio | End of the current fiscal period 39.5 / End of previous period 39.7 |
| Total assets | ¥8,761 million |
| Net assets | ¥3,645 million |
| Cash flows from operating activities | -135,573 Thousand yen |
| Cash flows from investing activities | -482,966 Thousand yen |
| Cash flows from financing activities | 152,613 Thousand yen |
| Cash and cash equivalents at end of period | 1,257,541 Thousand yen |
| Full-year earnings forecast | Net Sales ¥7,600 million (YoY -0.6%) / Operating profit ¥300 million (YoY -59.4%) / Ordinary income ¥250 million (YoY -63.0%) / Net income ¥150 million (YoY -72.4%) |
| Annual Dividend Forecast | 0 Yen → 0 Yen(0.0%) |
| Segment revenue | Life Science AI business 384,496 Thousand yen (YoY +40.3%), Risk management business 1,539,456 Thousand yen (YoY -24.2%), DX business 1,429,219 Thousand yen (YoY +32.7%) |
| Segment profit | Life Science AI business -149,455 Thousand yen, Risk management business -114,388 Thousand yen, DX business 68,934 Thousand yen (YoY +48.8%) |
| Depreciation and amortization | 224,236 Thousand yen |
| Impairment loss | ¥12.863 million: ¥6.504 million in internally used software in the Risk Management business and ¥6.358 million in prepaid expenses related to discontinued services. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of stock acquisition rights 5,607 Thousand yen, Gain on sale of shares in affiliates 47,044 Thousand yen, Gain on reversal of foreign currency translation adjustment 13,380 Thousand yen / Extraordinary loss Impairment loss 12,863 Thousand yen, Loss on disposal of property, plant and equipment 2,406 Thousand yen, Restructuring Costs 56,313 Thousand yen |
| Disclosure regarding the going concern assumption | There are no applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 1 company (FRONTEO Korea,Inc.) |
| Material subsequent events | There are no applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 39,412,362 |
| Treasury Shares at Period-End | 230,859 |
| Factors Behind Changes in Business Performance | The Life Science AI business posted higher revenue due to the accumulation of co-creation project contracts and DDAIF Innovation Bridge contracts, as well as one-time revenue related to AI medical device development. However, the business recorded an operating loss due to growth investments, including the expansion of its research staff. The Risk Management business posted lower revenue due to the cancellation of a major customer contract, delays in winning new projects, a decline in e-discovery projects, cancellations of private-sector projects, and the concentration of government projects in the second half. The DX business posted higher revenue and profit due to increased sales. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Life Science AI business posted higher revenue as projects accumulated, but recorded an operating loss due to growth investments, including the expansion of its research staff. The Risk Management business posted lower revenue and an operating loss due to the cancellation of a major customer contract, delays in winning new projects, a decline in e-discovery projects, cancellations of private-sector projects, and the concentration of government projects in the second half. The DX business posted higher revenue and profit due to increased sales.